Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 465

1.

Dual roles for the TSPYL family in mediating serotonin transport and the metabolism of selective serotonin reuptake inhibitors in MDD patients.

Qin S, Eugene AR, Liu D, Zhang L, Neavin D, Biernacka JM, Yu J, Weinshilboum RM, Wang L.

Clin Pharmacol Ther. 2019 Oct 19. doi: 10.1002/cpt.1692. [Epub ahead of print]

PMID:
31628858
2.

Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.

Zhu Y, Swanson KM, Rojas RL, Wang Z, St Sauver JL, Visscher SL, Prokop LJ, Bielinski SJ, Wang L, Weinshilboum R, Borah BJ.

Genet Med. 2019 Oct 8. doi: 10.1038/s41436-019-0667-y. [Epub ahead of print] Review.

PMID:
31591509
3.

Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment.

Bhattacharyya S, Dunlop BW, Mahmoudiandehkordi S, Ahmed AT, Louie G, Frye MA, Weinshilboum RM, Krishnan RR, Rush AJ, Mayberg HS, Craighead WE, Kaddurah-Daouk R.

Front Neurosci. 2019 Sep 12;13:926. doi: 10.3389/fnins.2019.00926. eCollection 2019.

4.

Integration of machine learning and pharmacogenomic biomarkers for predicting response to antidepressant treatment: can computational intelligence be used to augment clinical assessments?

Athreya AP, Iyer R, Wang L, Weinshilboum RM, Bobo WV.

Pharmacogenomics. 2019 Sep;20(14):983-988. doi: 10.2217/pgs-2019-0119. No abstract available.

5.

Pharmacogenomics in Practice.

Wang L, Weinshilboum R.

Clin Pharmacol Ther. 2019 Nov;106(5):936-938. doi: 10.1002/cpt.1600. Epub 2019 Sep 9. No abstract available.

PMID:
31498426
6.

Cohort Profile: The Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize Treatment Protocol (RIGHT Protocol).

Bielinski SJ, St Sauver JL, Olson JE, Larson NB, Black JL, Scherer SE, Bernard ME, Boerwinkle E, Borah BJ, Caraballo PJ, Curry TB, Doddapaneni H, Formea CM, Freimuth RR, Gibbs RA, Giri J, Hathcock MA, Hu J, Jacobson DJ, Jones LA, Kalla S, Koep TH, Korchina V, Kovar CL, Lee S, Liu H, Matey ET, McGree ME, McAllister TM, Moyer AM, Muzny DM, Nicholson WT, Oyen LJ, Qin X, Raj R, Roger VL, Rohrer Vitek CR, Ross JL, Sharp RR, Takahashi PY, Venner E, Walker K, Wang L, Wang Q, Wright JA, Wu TJ, Wang L, Weinshilboum RM.

Int J Epidemiol. 2019 Aug 4. pii: dyz123. doi: 10.1093/ije/dyz123. [Epub ahead of print] No abstract available.

PMID:
31378813
7.

Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer.

Ruddy KJ, Schaid DJ, Partridge AH, Larson NB, Batzler A, Häberle L, Dittrich R, Widschwendter P, Fink V, Bauer E, Schwitulla J, Rübner M, Ekici AB, Aivazova-Fuchs V, Stewart EA, Beckmann MW, Ginsburg E, Wang L, Weinshilboum RM, Couch FJ, Janni W, Rack B, Vachon C, Fasching PA.

Fertil Steril. 2019 Oct;112(4):731-739.e1. doi: 10.1016/j.fertnstert.2019.05.018. Epub 2019 Jul 29.

PMID:
31371054
8.

Single Nucleotide Polymorphisms at a Distance from Aryl Hydrocarbon Receptor (AHR) Binding Sites Influence AHR Ligand-Dependent Gene Expression.

Neavin DR, Lee JH, Liu D, Ye Z, Li H, Wang L, Ordog T, Weinshilboum RM.

Drug Metab Dispos. 2019 Sep;47(9):983-994. doi: 10.1124/dmd.119.087312. Epub 2019 Jul 10.

PMID:
31292129
9.

Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene.

Bodkin JA, Coleman MJ, Godfrey LJ, Carvalho CMB, Morgan CJ, Suckow RF, Anderson T, Öngür D, Kaufman MJ, Lewandowski KE, Siegel AJ, Waldstreicher E, Grochowski CM, Javitt DC, Rujescu D, Hebbring S, Weinshilboum R, Rodriguez SB, Kirchhoff C, Visscher T, Vuckovic A, Fialkowski A, McCarthy S, Malhotra D, Sebat J, Goff DC, Hudson JI, Lupski JR, Coyle JT, Rudolph U, Levy DL.

Biol Psychiatry. 2019 Oct 1;86(7):523-535. doi: 10.1016/j.biopsych.2019.04.031. Epub 2019 May 9.

PMID:
31279534
10.

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.

Bhattacharyya S, Ahmed AT, Arnold M, Liu D, Luo C, Zhu H, Mahmoudiandehkordi S, Neavin D, Louie G, Dunlop BW, Frye MA, Wang L, Weinshilboum RM, Krishnan RR, Rush AJ, Kaddurah-Daouk R.

Transl Psychiatry. 2019 Jul 4;9(1):173. doi: 10.1038/s41398-019-0507-5.

11.

Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall.

Moyer AM, Yu J, Sinnwell JP, Dockter TJ, Suman VJ, Weinshilboum RM, Boughey JC, Goetz MP, Visscher DW, Wang L.

Oncotarget. 2019 Jun 11;10(39):3924-3930. doi: 10.18632/oncotarget.27001. eCollection 2019 Jun 11.

12.

Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.

Ingle JN, Kalari KR, Momozawa Y, Kubo M, Furukawa Y, Shepherd LE, Ellis MJ, Goss PE, Barman P, Carlson EE, Sinnwell JP, Tang X, Goetz MP, Chen BE, Cairns J, Weinshilboum RM, Wang L.

Pharmacogenet Genomics. 2019 Oct;29(8):183-191. doi: 10.1097/FPC.0000000000000382.

PMID:
31211741
13.

Comparison of 99mTc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy.

Hunt KN, Conners AL, Goetz MP, O'Connor MK, Suman V, Kalari K, Weinshilboum R, Wang L, Carter J, McLaughlin S, Aspitia AM, Gray R, Northfelt D, Boughey JC.

AJR Am J Roentgenol. 2019 Oct;213(4):932-943. doi: 10.2214/AJR.18.20628. Epub 2019 Jun 5.

PMID:
31166752
14.

Catechol O-Methyltransferase Pharmacogenomics: Challenges and Opportunities.

Ho MF, Weinshilboum RM.

Clin Pharmacol Ther. 2019 Aug;106(2):281-283. doi: 10.1002/cpt.1452. Epub 2019 May 13. No abstract available.

15.

Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.

Athreya AP, Neavin D, Carrillo-Roa T, Skime M, Biernacka J, Frye MA, Rush AJ, Wang L, Binder EB, Iyer RK, Weinshilboum RM, Bobo WV.

Clin Pharmacol Ther. 2019 Oct;106(4):855-865. doi: 10.1002/cpt.1482. Epub 2019 Jun 29.

16.

Clopidogrel Pharmacogenetics.

Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, Goodman SG, Weinshilboum RM, Wang L, Baudhuin LM, Lerman A, Hasan A, Iturriaga E, Fu YP, Geller N, Bailey K, Farkouh ME.

Circ Cardiovasc Interv. 2019 Apr;12(4):e007811. doi: 10.1161/CIRCINTERVENTIONS.119.007811.

PMID:
30998396
17.

The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.

Cairns J, Ingle JN, Kalari KR, Shepherd LE, Kubo M, Goetz MP, Weinshilboum RM, Wang L.

Breast Cancer Res. 2019 Apr 3;21(1):47. doi: 10.1186/s13058-019-1130-3.

18.

4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.

Wang G, Qin S, Zayas J, Ingle JN, Liu M, Weinshilboum RM, Shen K, Wang L.

Breast Cancer Res Treat. 2019 Jun;175(3):567-578. doi: 10.1007/s10549-019-05194-z. Epub 2019 Apr 1.

PMID:
30937657
19.

Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons.

Vadodaria KC, Ji Y, Skime M, Paquola AC, Nelson T, Hall-Flavin D, Heard KJ, Fredlender C, Deng Y, Elkins J, Dani K, Le AT, Marchetto MC, Weinshilboum R, Gage FH.

Mol Psychiatry. 2019 Jun;24(6):808-818. doi: 10.1038/s41380-019-0377-5. Epub 2019 Mar 22.

PMID:
30903001
20.

Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19.

Devarajan S, Moon I, Ho MF, Larson NB, Neavin DR, Moyer AM, Black JL, Bielinski SJ, Scherer SE, Wang L, Weinshilboum RM, Reid JM.

Drug Metab Dispos. 2019 Apr;47(4):425-435. doi: 10.1124/dmd.118.084269. Epub 2019 Feb 11.

PMID:
30745309
21.

Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons.

Vadodaria KC, Ji Y, Skime M, Paquola A, Nelson T, Hall-Flavin D, Fredlender C, Heard KJ, Deng Y, Le AT, Dave S, Fung L, Li X, Marchetto MC, Weinshilboum R, Gage FH.

Mol Psychiatry. 2019 Jun;24(6):795-807. doi: 10.1038/s41380-019-0363-y. Epub 2019 Jan 30.

PMID:
30700803
22.

The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer.

Zhuang Y, Ly RC, Frazier CV, Yu J, Qin S, Fan XY, Goetz MP, Boughey JC, Weinshilboum R, Wang L.

Cancer Metab. 2019 Jan 24;7:1. doi: 10.1186/s40170-018-0193-4. eCollection 2019.

23.

PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient.

Kalari KR, Sinnwell JP, Thompson KJ, Tang X, Carlson EE, Yu J, Vedell PT, Ingle JN, Weinshilboum RM, Boughey JC, Wang L, Goetz MP, Suman V.

JCO Clin Cancer Inform. 2018 Dec;2:1-11. doi: 10.1200/CCI.18.00012.

24.

Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.

Dudenkov TM, Liu D, Cairns J, Devarajan S, Zhuang Y, Ingle JN, Buzdar AU, Robson ME, Kubo M, Batzler A, Barman P, Jenkins GD, Carlson EE, Goetz MP, Northfelt DW, Moreno-Aspitia A, Desta Z, Reid JM, Kalari KR, Wang L, Weinshilboum RM.

Clin Pharmacol Ther. 2019 Jul;106(1):219-227. doi: 10.1002/cpt.1359. Epub 2019 Mar 18.

25.

The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression.

Amare AT, Schubert KO, Tekola-Ayele F, Hsu YH, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Kato M, Liu YL, Praphanphoj V, Stingl JC, Bobo WV, Tsai SJ, Kubo M, Klein TE, Weinshilboum RM, Biernacka JM, Baune BT.

J Neural Transm (Vienna). 2019 Jan;126(1):35-45. doi: 10.1007/s00702-018-01966-x. Epub 2019 Jan 4.

PMID:
30610379
26.

Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.

Ahmed AT, Biernacka JM, Jenkins G, Rush AJ, Shinozaki G, Veldic M, Kung S, Bobo WV, Hall-Flavin DK, Weinshilboum RM, Wang L, Frye MA.

J Affect Disord. 2019 Mar 1;246:62-68. doi: 10.1016/j.jad.2018.12.021. Epub 2018 Dec 17.

27.

The Role of the Aryl Hydrocarbon Receptor (AHR) in Immune and Inflammatory Diseases.

Neavin DR, Liu D, Ray B, Weinshilboum RM.

Int J Mol Sci. 2018 Dec 3;19(12). pii: E3851. doi: 10.3390/ijms19123851. Review.

28.

Augmentation of Physician Assessments with Multi-Omics Enhances Predictability of Drug Response: A Case Study of Major Depressive Disorder.

Athreya A, Iyer R, Neavin D, Wang L, Weinshilboum R, Kaddurah-Daouk R, Rush J, Frye M, Bobo W.

IEEE Comput Intell Mag. 2018 Aug;13(3):20-31. doi: 10.1109/MCI.2018.2840660. Epub 2018 Jul 20.

29.

Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts.

Ward J, Graham N, Strawbridge RJ, Ferguson A, Jenkins G, Chen W, Hodgson K, Frye M, Weinshilboum R, Uher R, Lewis CM, Biernacka J, Smith DJ.

PLoS One. 2018 Sep 21;13(9):e0203896. doi: 10.1371/journal.pone.0203896. eCollection 2018.

30.

Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.

Fabbri C, Tansey KE, Perlis RH, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Breen G, Curtis C, Lee SH, Newhouse S, Patel H, O'Donovan M, Lewis G, Jenkins G, Weinshilboum RM, Farmer A, Aitchison KJ, Craig I, McGuffin P, Schruers K, Biernacka JM, Uher R, Lewis CM.

Eur Neuropsychopharmacol. 2018 Aug;28(8):945-954. doi: 10.1016/j.euroneuro.2018.05.009. Epub 2018 Jun 28.

PMID:
30135031
31.

Machine Learning Helps Identify New Drug Mechanisms in Triple-Negative Breast Cancer.

Athreya AP, Gaglio AJ, Cairns J, Kalari KR, Weinshilboum RM, Wang L, Kalbarczyk ZT, Iyer RK.

IEEE Trans Nanobioscience. 2018 Jul;17(3):251-259. doi: 10.1109/TNB.2018.2851997. Epub 2018 Jul 2.

32.

Single Nucleotide Polymorphisms (SNPs) Distant from Xenobiotic Response Elements Can Modulate Aryl Hydrocarbon Receptor Function: SNP-Dependent CYP1A1 Induction.

Liu D, Qin S, Ray B, Kalari KR, Wang L, Weinshilboum RM.

Drug Metab Dispos. 2018 Sep;46(9):1372-1381. doi: 10.1124/dmd.118.082164. Epub 2018 Jul 6. Erratum in: Drug Metab Dispos. 2019 Mar;47(3):270.

33.

Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders.

Ahmed AT, Frye MA, Rush AJ, Biernacka JM, Craighead WE, McDonald WM, Bobo WV, Riva-Posse P, Tye SJ, Mayberg HS, Hall-Flavin DK, Skime MK, Jenkins GD, Wang L, Krishnan RR, Weinshilboum RM, Kaddurah-Daouk R, Dunlop BW; Mood Disorders Precision Medicine Consortium (MDPMC).

J Affect Disord. 2018 Oct 1;238:1-7. doi: 10.1016/j.jad.2018.05.005. Epub 2018 May 26.

34.

Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients.

Taylor JC, Bongartz T, Massey J, Mifsud B, Spiliopoulou A, Scott IC, Wang J, Morgan M, Plant D, Colombo M, Orchard P, Twigg S, McInnes IB, Porter D, Freeston JE, Nam JL, Cordell HJ, Isaacs JD, Strathdee JL, Arnett D, de Hair MJH, Tak PP, Aslibekyan S, van Vollenhoven RF, Padyukov L, Bridges SL, Pitzalis C, Cope AP, Verstappen SMM, Emery P, Barnes MR, Agakov F, McKeigue P, Mushiroda T, Kubo M, Weinshilboum R, Barton A, Morgan AW, Barrett JH; MATURA; and PAMERA; Consortia.

Pharmacogenomics J. 2018 Jul;18(4):528-538. doi: 10.1038/s41397-018-0025-5. Epub 2018 May 25. Review.

35.

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.

Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm T, Huober J, Liedtke C, Weinshilboum RM, Wang L, Ingle JN, Müller V, Nekljudova V, Weber KE, Rack B, Rübner M, von Minckwitz G, Couch FJ.

J Clin Oncol. 2018 Aug 1;36(22):2281-2287. doi: 10.1200/JCO.2017.77.2285. Epub 2018 May 23.

36.

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab.

Ingle JN, Kalari KR, Wickerham DL, von Minckwitz G, Fasching PA, Furukawa Y, Mushiroda T, Goetz MP, Barman P, Carlson EE, Rastogi P, Costantino JP, Cairns J, Paik S, Bear HD, Kubo M, Wang L, Wolmark N, Weinshilboum RM.

Pharmacogenet Genomics. 2018 Jun;28(6):147-152. doi: 10.1097/FPC.0000000000000337.

37.

SLCO1B1 genetic variation and hormone therapy in menopausal women.

Moyer AM, de Andrade M, Faubion SS, Kapoor E, Dudenkov T, Weinshilboum RM, Miller VM.

Menopause. 2018 Aug;25(8):877-882. doi: 10.1097/GME.0000000000001109.

38.

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.

Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, Zhuang Y, Liu D, Lu SW, Kalari KR, Visscher DW, Copland JA, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Lou Z, Suman VJ, Weinshilboum R, Boughey JC, Goetz MP, Wang L.

J Clin Invest. 2018 Jun 1;128(6):2376-2388. doi: 10.1172/JCI97924. Epub 2018 Apr 30.

39.

Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression.

Ho MF, Correia C, Ingle JN, Kaddurah-Daouk R, Wang L, Kaufmann SH, Weinshilboum RM.

Biochem Pharmacol. 2018 Jun;152:279-292. doi: 10.1016/j.bcp.2018.03.032. Epub 2018 Apr 3.

40.

Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients.

Bidadi B, Liu D, Kalari KR, Rubner M, Hein A, Beckmann MW, Rack B, Janni W, Fasching PA, Weinshilboum RM, Wang L.

Front Pharmacol. 2018 Mar 13;9:158. doi: 10.3389/fphar.2018.00158. eCollection 2018.

41.

TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor κB p65: Single Nucleotide Polymorphism and Estrogen Dependence.

Ho MF, Lummertz da Rocha E, Zhang C, Ingle JN, Goss PE, Shepherd LE, Kubo M, Wang L, Li H, Weinshilboum RM.

J Pharmacol Exp Ther. 2018 Jun;365(3):700-710. doi: 10.1124/jpet.118.247718. Epub 2018 Mar 28.

42.

Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.

Amare AT, Schubert KO, Tekola-Ayele F, Hsu YH, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Kato M, Liu YL, Praphanphoj V, Stingl JC, Bobo WV, Tsai SJ, Kubo M, Klein TE, Weinshilboum RM, Biernacka JM, Baune BT.

Front Psychiatry. 2018 Mar 6;9:65. doi: 10.3389/fpsyt.2018.00065. eCollection 2018.

43.

Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.

Volpi S, Bult CJ, Chisholm RL, Deverka PA, Ginsburg GS, Jacob HJ, Kasapi M, McLeod HL, Roden DM, Williams MS, Green ED, Rodriguez LL, Aronson S, Cavallari LH, Denny JC, Dressler LG, Johnson JA, Klein TE, Leeder JS, Piquette-Miller M, Perera M, Rasmussen-Torvik LJ, Rehm HL, Ritchie MD, Skaar TC, Wagle N, Weinshilboum R, Weitzel KW, Wildin R, Wilson J, Manolio TA, Relling MV.

Clin Pharmacol Ther. 2018 May;103(5):778-786. doi: 10.1002/cpt.1048. Epub 2018 Mar 30. Review.

44.

Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder.

Ahmed AT, Weinshilboum R, Frye MA.

Clin Pharmacol Ther. 2018 May;103(5):767-769. doi: 10.1002/cpt.1009. Epub 2018 Feb 1.

45.

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics.

Liu D, Ray B, Neavin DR, Zhang J, Athreya AP, Biernacka JM, Bobo WV, Hall-Flavin DK, Skime MK, Zhu H, Jenkins GD, Batzler A, Kalari KR, Boakye-Agyeman F, Matson WR, Bhasin SS, Mushiroda T, Nakamura Y, Kubo M, Iyer RK, Wang L, Frye MA, Kaddurah-Daouk R, Weinshilboum RM.

Transl Psychiatry. 2018 Jan 10;8(1):10. doi: 10.1038/s41398-017-0056-8.

46.

Considerations for automated machine learning in clinical metabolic profiling: Altered homocysteine plasma concentration associated with metformin exposure.

Orlenko A, Moore JH, Orzechowski P, Olson RS, Cairns J, Caraballo PJ, Weinshilboum RM, Wang L, Breitenstein MK.

Pac Symp Biocomput. 2018;23:460-471.

47.

Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.

Yu J, Qin B, Moyer AM, Sinnwell JP, Thompson KJ, Copland JA 3rd, Marlow LA, Miller JL, Yin P, Gao B, Minter-Dykhouse K, Tang X, McLaughlin SA, Moreno-Aspitia A, Schweitzer A, Lu Y, Hubbard J, Northfelt DW, Gray RJ, Hunt K, Conners AL, Suman VJ, Kalari KR, Ingle JN, Lou Z, Visscher DW, Weinshilboum R, Boughey JC, Goetz MP, Wang L.

Breast Cancer Res. 2017 Dec 6;19(1):130. doi: 10.1186/s13058-017-0920-8.

48.

A comprehensive analysis of breast cancer microbiota and host gene expression.

Thompson KJ, Ingle JN, Tang X, Chia N, Jeraldo PR, Walther-Antonio MR, Kandimalla KK, Johnson S, Yao JZ, Harrington SC, Suman VJ, Wang L, Weinshilboum RL, Boughey JC, Kocher JP, Nelson H, Goetz MP, Kalari KR.

PLoS One. 2017 Nov 30;12(11):e0188873. doi: 10.1371/journal.pone.0188873. eCollection 2017.

49.

New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation.

Fabbri C, Tansey KE, Perlis RH, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Breen G, Curtis C, Sang-Hyuk L, Newhouse S, Patel H, Guipponi M, Perroud N, Bondolfi G, O'Donovan M, Lewis G, Biernacka JM, Weinshilboum RM, Farmer A, Aitchison KJ, Craig I, McGuffin P, Uher R, Lewis CM.

Pharmacogenomics J. 2018 May 22;18(3):413-421. doi: 10.1038/tpj.2017.44. Epub 2017 Nov 21.

PMID:
29160301
50.

Pharmacogenomics: Precision Medicine and Drug Response.

Weinshilboum RM, Wang L.

Mayo Clin Proc. 2017 Nov;92(11):1711-1722. doi: 10.1016/j.mayocp.2017.09.001. Epub 2017 Nov 1. Review.

Supplemental Content

Loading ...
Support Center